



## ARUP's Nontraditional High-Resolution Hybrid Drug Panel Reduces Costs and Saves Time

Features and benefits include:


- Comprehensive, high-resolution results for 47 drugs and metabolites
- Significant decrease in time and testing expenses
- Reduction in need for most confirmation testing
- Now available with interpretation



Now available with interpretation

ARUP's hybrid panel provides results that are granular and highly specific. This makes traditional confirmation tests unnecessary. The hybrid panel reports every analyte examined.

The enhanced report also provides a summary of drugs detected. For an additional fee, interpretation based on patient medication is available.



Codeine	-
Morphine	-
6-acetylmorphine	-
Oxycodone	+
Noroxycodone	+
Oxymorphone	+
Noroxymorphone	+
Hydrocodone	-
Dihydrocodeine	-
Norhydrocodone	-
Hydromorphone	-
Alprazolam	-
Clonazepam	-
Oxazepam	-
Lorazepam	+
Barbituates	-

Oxycodone	Present
Noroxycodone	Present
Oxymorphone	Present
Noroxymorphone	Present
Lorazepam	Present

**INTERPRETIVE CONSULTATION:**

Drugs expected: Ativan, Percocet

**CONSISTENT** with medications provided:

Ativan: Based on lorazepam

Percocet: Based on oxycodone, oxymorphone, noroxymorphone

## Pain Management Testing Strategies That Save Time and Money

The high-resolution hybrid urine drug panel may be used as a primary drug screen or as a secondary confirmation after a point-of-care screen/cup, saving time and money compared to traditional drug testing strategies.

## Resolving Unanswered Questions

Immunoassay screens and point-of-care cups may report opiates as a class but not as individual drugs, leaving certain questions unanswered: What was positive? What was tested? Benzodiazepines, for example, tend to be a source of false negatives, as they are poorly sensitive to the metabolite of clonazepam. ARUP's high-resolution drug panel uses advanced technologies, reducing unexpected or ambiguous results and the need for costly confirmation testing.

### Primary screen recommended reimbursement codes:

80101x8 and 80100; for Medicare: G0431

### Secondary confirmation recommended reimbursement codes:

80101x3\*, 80100, and 80102; for Medicare: G0431 and 80102

\*Multiplier will depend on the device used in the first screen

## Test Ordering Information

<b>Test Name</b>	Pain Management Drug Panel by High-Resolution Time-of-Flight Mass Spectrometry and Enzyme Immunoassay, Urine
<b>Test Code</b>	2007479
<b>Method</b>	Qualitative liquid chromatography/TOF mass spectrometry/enzyme immunoassay/quantitative spectrophotometry

## Now Available with Interpretation

<b>Test Name</b>	Pain Management Drug Screen with Interpretation by High-Resolution Time-of-Flight Mass Spectrometry and Enzyme Immunoassay, Urine
<b>Test Code</b>	2009288

Patient medication information must be provided to receive interpretation.

To see a sample report, please visit:

[www.aruplab.com/pain-hybrid](http://www.aruplab.com/pain-hybrid)

## List of Drugs Reported in the High-Resolution Hybrid Urine Drug Panel:

### OPIATES/OPIOIDS

6-acetylmorphine (heroin metabolite)  
Buprenorphine  
Buprenorphine-glucuronide  
Norbuprenorphine  
Codeine  
Fentanyl  
Norfentanyl  
Hydrocodone  
Dihydrocodeine

Norhydrocodone  
Hydromorphone  
Meperidine metabolite  
Methadone\*  
Morphine  
Oxycodone  
Noroxycodone  
Oxymorphone  
Noroxymorphone  
Propoxyphene\*  
Tapentadol

Tapentadol-o-sulfate  
Tramadol\*

### AMPHETAMINES

Amphetamine  
Methamphetamine  
MDMA—Ecstasy  
MDA  
MDEA—Eve  
Ritalinic acid (methylphenidate)  
Phentermine

### BENZODIAZEPINES

Alprazolam  
—Alpha-OH-alprazolam  
Clonazepam  
—7-aminoclonazepam  
Diazepam  
Nordiazepam  
Oxazepam  
Temazepam  
Lorazepam  
Midazolam

Zolpidem

### OTHER\*\*

Barbiturates  
Carisoprodol/meprobamate  
Cocaine metabolite  
Marijuana metabolite  
PCP  
Ethyl glucuronide  
Creatinine

\*\*Analyzed by immunoassay or spectrophotometry

## Pain Management Experts

ARUP's Pain Management Division consists of experts who are faculty members at the University of Utah School of Medicine. They provide a full range of consultative and diagnostic services.



**Gwendolyn A. McMillin**  
PhD, DABCC (CC,TC)  
Medical Director,  
Toxicology and  
Pharmacogenetics



**Kamisha Johnson-Davis**  
PhD, DABCC (CC)  
Medical Director, Toxicology



**Frederick G. Strathmann**  
PhD, DABCC (CC,TC)  
Medical Director,  
Toxicology



PHONE: (800) 522-2787

[WWW.ARUPLAB.COM/PAIN-MANAGEMENT](http://WWW.ARUPLAB.COM/PAIN-MANAGEMENT)